HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

June 2021

Love and a Lab Coat: One Couple’s Quest to Treat Alzheimer Disease

June 20, 2021


Luca Giliberto, MD, PhD, and Cristina d’Abramo, PhD, share more than a marriage: After years of research, their combined efforts to develop a passive immunotherapy for Alzheimer disease have earned them a $2 million grant from the National Institutes of Health.

Managing the Intricacies and Age-Specific Challenges of Pediatric Multiple Sclerosis

June 17, 2021

NeurologyLive Insights

Two experts in pediatric MS care, Lauren B. Krupp, MD, and Tanuja Chitnis, MD, offer tips and insight on the diagnosis of the disease and the specific challenges faced by patients stemming from their own clinical experience.

Myostatin Inhibition in Amyotrophic Lateral Sclerosis

June 16, 2021


ALS has only recently been associated with causative or disease-modifying mutations in 20 genes that encode proteins with diverse functions, with promising therapeutic targets including proteins in pathways that regulate protein homeostasis.

Do We Finally Have a Useful “Sed Rate” for Multiple Sclerosis?

June 15, 2021

Letter From the Editor

All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.

Aducanumab for Alzheimer Disease: Landmark Moment or False Hope for Patients?

June 08, 2021

Clinical Viewpoint

Experts in the treatment and management of patients with Alzheimer disease and dementia, including Marwan Sabbagh, MD; Lon Schneider, MD, MS; Anton Porsteinsson, MD; and Robert Howard, MD, MRCPsych, weigh in on the FDA's controversial approval of Biogen's anti-amyloid drug, aducanumab.

Lecanemab (BAN2401) Reduces Amyloid in Alzheimer Disease Across 18-Month Study

May 06, 2021

In the Headlines

Findings on multiple cognitive end points and biomarkers support lecanemab’s therapeutic concept for the targeting of specific oligomeric species in the process of pathophysiological amyloid generation in Alzheimer disease.